期刊文献+

基于氧化应激探讨毓麟珠调控TSC/Akt通路改善免疫性POI小鼠卵巢功能的机制研究 被引量:6

Study on the regulation of TSC/Akt pathway by Yulinzhu to improve ovarian function in immune POI mice based on oxidative stress mechanism
下载PDF
导出
摘要 目的探讨毓麟珠调控TSC/Akt通路改善氧化应激,进而改善卵泡发育的机制。方法动情周期正常的84只雌性BALB/c小鼠随机分为空白组、模型组、雌激素组、毓麟珠组(低、中、高剂量组),每组14只。除空白组外,其余五组建立免疫性早发性卵巢功能不全(primary ovarian insufficiency,POI)模型。造模成功后,除空白组、模型组外,其余各组连续6周给予相应药物灌胃治疗。治疗后,观察卵巢组织病理状态,检测卵巢组织的超氧化物歧化酶(superoxide dismutase,SOD)、活性氧(reactive oxygen species,ROS)、谷胱甘肽过氧化物酶(glutathione peroxidase,GSH-Px)和丙二醛(malondialdehyde,MDA)的水平,蛋白免疫印迹法检测卵巢组织中RheB、P-s6k1、P-4E-BP1蛋白含量的表达,免疫组化检测卵巢组织中TSC1、TSC2、Akt的蛋白表达。结果造模成功后,模型组小鼠卵巢、子宫质量降低;给药后,毓麟珠高剂量组小鼠左右卵巢以及子宫质量均增加(P<0.01)。与模型组相比,各给药组卵泡数量明显增加,卵巢组织形态明显改善。与空白组相比,模型组氧化因子表达水平较高,抗氧化因子表达水平明显较低(P<0.05);与模型组相比,各给药组ROS、MDA明显升高,GSH-Px、SOD明显降低(P<0.05)。与空白组相比,模型组Akt蛋白表达降低,TSC1、TSC2表达升高;与模型组相比,各给药组Akt蛋白表达明显升高,TSC1、TSC2蛋白表达明显降低。与空白组相比,模型组RheB、P-s6k1、P-4E-BP1表达降低(P<0.05);与模型组相比,各给药组RheB、P-s6k1、P-4E-BP1蛋白表达升高,以P-4E-BP1升高最明显(P<0.01)。结论毓麟珠通过调控TSC/Akt信号通路抑制微环境氧化应激,这可能是其改善卵母细胞质量,促进卵母细胞成熟的作用机制。 Objective The destination of this paper was to discuss the regulation of TSC/Akt pathway by Yulinzhu to improve oxidative stress,and then improve the mechanism of follicle development.Methods 84 female BALB/c mice with normal emotional cycle were selected,they were randomly divided into blank group,model group,estrogen group and Yulinzhu group(low,medium and high dose group).Except for the blank group,five other groups established immune POI models.After the model established,except for the blank group,the model group,the other groups were given corresponding drugs for 6 weeks.Observe the pathological state of ovarian tissue by HE staining,observe the oxidative stress state of ovary by detecting the levels of superoxide dismutase(SOD),active oxygen(ROS),glutathione peroxidase(GSH-Px)and malondialdehyde(MDA)in ovarian tissues,and detect the expression of RheB,P-s6k1,P-4E-BP1 protein content in ovarian tissues by Western blot,TSC1,TSC2,Akt protein expression in ovarian tissues was detected by immunohistochemistry.Results The weight of ovary and uterus in mice showed that the quality of ovary in the model group was decreased,after administration.The quality of left and right ovaries and uterus of mice in the Yulinzhu high dose group increased,difference was statistically significant(P<0.01).The HE results show that compared with the model group,The number of follicles in each group increased significantly,the morphology of ovarian tissue was obviously improved;the results of oxidative stress factor test showed that the expression of oxidative stress factor was higher in the model group,the expression of antioxidant factors was significantly lower,after administration,the ROS,MDA increased significantly,GSH-Px,SOD significantly reduced,difference was statistically significant(P<0.05);the immunohistochemical results showed that Akt protein expression was decreased and TSC1,TSC2 protein expression were increased in the model group.After administration,the Akt protein expression was increased significantly,the TSC1,TSC2 protein expression were decreased significantly;the Western blotting showed that the expressions of RheB,P-s6k1,P-4E-BP1 in the model group were decreased,the expressions of RheB,P-s6k1,P-4E-BP1 protein in the administration group were increased significantly,difference was statistically significant(P<0.05).Conclusion Yulinzhu regulates the TSC/Akt signal pathway,through the mechanism of inhibiting microenvironment oxidative stress.This may be the mechanism for improving oocyte quality and promoting oocyte maturation.
作者 魏茂林 杨珍 董晓英 冯逊逊 WEI Maolin;YANG Zhen;DONG Xiaoying;FENG Xunxun(School of Traditional Chinese Medicine,Capital Medical University,Beijing 100069,China)
出处 《环球中医药》 CAS 2021年第12期2127-2134,共8页 Global Traditional Chinese Medicine
基金 北京市自然科学基金面上项目(7212162) 北京中医药薪火传承“3+3”工程(2012-SZ-C-41)。
关键词 早发性卵巢功能不全 毓麟珠 TSC/Akt通路 氧化应激 Primary ovarian insufficiency Yulinzhu TSC/Akt pathway Oxidative stress
  • 相关文献

参考文献14

二级参考文献79

  • 1付莉,赵怡璇,李守柔.卵巢早衰实验动物模型的建立[J].生殖医学杂志,2006,15(3):179-183. 被引量:46
  • 2[4]ww.fda.gov/cder/cancer/animalframe.htm
  • 3[5]FDA Guidance for industry and reviewers: Estimating the safe starting dose in clinical trials for therapeutics in adult healthy volunteers[ S]. 2002; 12
  • 4[6]FDA Guidance for Industry: food-effect bioavailability and fed bioequivalence studies[ S]. 2002; 12
  • 5Horejsi J,Novakova D,Martinek J.Circulating ovarian autoantibodies and FSH and LH levels in adolescent girls with primary menstrual cycle disorders[J].J Pediatr Adolesc Gynecol,1996,9(2):74-78.
  • 6Lou YH,Park KK,Agersborg S,et al.Retargeting T cellmediated inflammation:a new perspective on autoantibody action[J].J Immunol,2000,164(10):5251-5257.
  • 7Bagavant H,Sharp C,Kurth B,et al.Induction and immunohistology of autoimmune ovarian disease in cynomolgus macaques (Macaca fascicularis)[J].Am J Pathol,2002,160(1):141-149.
  • 8Damjanovic M,Jankovic BD.Experimental autoimmune oophoritis.I.Inhibition of fertility in rats isoimmunized with homogenates of ovary[J].Am J Reprod Immunol,1989,20(1):1-8.
  • 9Nelson LM.Autoimmune ovarian failure:comparing the mouse model and the human disease[J].J Soc Gynecol Investig,2001,8(1):55-57.
  • 10Kalantaridou SN,Nelson LM.Autoimmune premature ovarian:failure:of mice and women[J].J Am Med Womens Assoc,1998,53(1):18-20.

共引文献1783

同被引文献104

引证文献6

二级引证文献9

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部